Compare RNST & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RNST | TWST |
|---|---|---|
| Founded | 1904 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.0B |
| IPO Year | 1994 | 2018 |
| Metric | RNST | TWST |
|---|---|---|
| Price | $36.06 | $42.68 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 8 |
| Target Price | $42.25 | ★ $48.75 |
| AVG Volume (30 Days) | 647.5K | ★ 1.1M |
| Earning Date | 04-27-2026 | 05-04-2026 |
| Dividend Yield | ★ 2.54% | N/A |
| EPS Growth | N/A | ★ 63.89 |
| EPS | ★ 2.07 | N/A |
| Revenue | N/A | ★ $376,572,000.00 |
| Revenue This Year | $31.83 | $18.89 |
| Revenue Next Year | $4.58 | $15.28 |
| P/E Ratio | $17.53 | ★ N/A |
| Revenue Growth | N/A | ★ 20.32 |
| 52 Week Low | $27.26 | $23.30 |
| 52 Week High | $42.11 | $57.88 |
| Indicator | RNST | TWST |
|---|---|---|
| Relative Strength Index (RSI) | 34.99 | 42.10 |
| Support Level | $35.45 | $42.89 |
| Resistance Level | $37.99 | $45.76 |
| Average True Range (ATR) | 1.26 | 2.63 |
| MACD | -0.44 | -0.83 |
| Stochastic Oscillator | 14.54 | 6.34 |
Renasant Corp operates as a holding company for Renasant Bank, a Mississippi banking corporation, and its subsidiary, Renasant Insurance, Inc. It has three reportable segments: Community banks, Insurance, and Wealth management. With its Community banks segment, the company provides a range of financial services to individuals and small businesses. Its Insurance segment is an insurance agency providing commercial and personal insurance through third-party carriers. The Wealth management segment provides a range of services, including money management and retirement planning. The majority of the company's revenue is driven by lending activities in its community banks segment.
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.